Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables - Other for 9 consecutive years, with $194000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Other changed N/A to $194000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $194000.0, a N/A change, with the full-year FY2025 number at $194000.0, changed N/A from a year prior.
  • Receivables - Other was $194000.0 for Q4 2025 at Akebia Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $9.5 million in Q2 2022 to a low of $194000.0 in Q4 2025.
  • A 5-year average of $2.6 million and a median of $1.9 million in 2022 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 634.62% in 2022; the steepest drop was 94.19% in 2022.
  • Akebia Therapeutics' Receivables - Other stood at $4.3 million in 2021, then crashed by 55.88% to $1.9 million in 2022, then skyrocketed by 75.33% to $3.3 million in 2023, then tumbled by 45.24% to $1.8 million in 2024, then crashed by 89.37% to $194000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables - Other are $194000.0 (Q4 2025), $5.4 million (Q2 2025), and $400000.0 (Q1 2025).